Printed on 3/17/2026
For informational purposes only. This is not medical advice.
The Eastern Cooperative Oncology Group (ECOG) Performance Status describes a patient's level of functioning in terms of self-care, daily activity, and physical ability. Scores range 0–5 and are critical for determining chemotherapy eligibility, clinical trial enrollment, and prognostic estimation in oncology. Calculate chemotherapy doses with [BSA Calculator](/tools/bsa-calculator). For elderly oncology patients, complement with [Clinical Frailty Scale](/tools/clinical-frailty) and [Katz ADL Index](/tools/katz-adl). Monitor renal function for cisplatin eligibility with [eGFR Calculator](/tools/egfr-calculator). Assess prostate cancer-specific risk with [CAPRA Score](/tools/capra-score).
Formula: 0: Fully active. 1: Restricted in strenuous activity. 2: Ambulatory, self-care, no work. 3: Limited self-care, confined >50%. 4: Completely disabled.
The ECOG Performance Status (also called WHO Performance Status or Zubrod Score) is a simple, validated scale that quantifies a cancer patient's overall functional capacity on a scale from 0 (fully active) to 5 (dead). Assessment requires observing the patient's ability to perform daily activities, work, self-care tasks, and ambulation, and correlating this with patient and family reports of baseline function. Start by asking the patient (and family members if available) about their current activity level compared to before their cancer diagnosis: 'What activities are you able to do now compared to before you got sick? Are you working? Can you do housework, shopping, cooking? How much of your day do you spend in bed or sitting in a chair? Can you take care of your personal hygiene (bathing, dressing) without help?' Observe the patient during the clinic visit: Are they ambulatory or wheelchair-bound? Do they appear fatigued or robust? Are they dressed and groomed or disheveled? Can they walk without assistance? Do they require help standing from a seated position? These observations, combined with patient/family reports, provide the data needed to assign an ECOG score. The assessment should take <1–2 minutes and can be integrated naturally into the history and physical exam.
Apply the ECOG Performance Status definitions systematically: **ECOG 0 (Fully active):** The patient is able to carry on all pre-disease performance without restriction. They can work full-time, perform strenuous activities (exercise, sports, heavy housework), and have no limitations from their cancer or treatment. This is the patient who 'doesn't look sick'—they may have recently completed chemotherapy or radiation but remain fully functional. Example: A 58-year-old with early-stage breast cancer undergoing adjuvant chemotherapy who continues working as a teacher, exercises 3x/week, and manages all household tasks independently. **ECOG 1 (Restricted in strenuous activity):** The patient has some symptoms but is fully ambulatory. They cannot do strenuous physical work but can perform light or sedentary work (office job, light housekeeping). They are up and about >50% of waking hours. Example: A 65-year-old with metastatic colon cancer who can do grocery shopping and cook but cannot mow the lawn, and who retired from physically demanding construction work but could handle desk work. **ECOG 2 (Ambulatory, capable of self-care, unable to work):** The patient is ambulatory and capable of all self-care (bathing, dressing, eating) but unable to carry out any work activities. They are out of bed or chair >50% of waking hours but spend significant time resting. Example: A 72-year-old with metastatic lung cancer who can bathe and dress himself, walk around the house, and make simple meals, but spends most afternoons napping and cannot do yard work or prolonged activities. **ECOG 3 (Limited self-care, confined >50%):** The patient is capable of only limited self-care and is confined to bed or chair >50% of waking hours. They may need help with bathing, dressing, or preparing meals. Example: A 68-year-old with advanced pancreatic cancer who can walk to the bathroom and feed himself but requires assistance with bathing, spends most of the day in a recliner, and cannot prepare meals. **ECOG 4 (Completely disabled):** The patient is completely disabled, cannot carry on any self-care, and is totally confined to bed or chair. They require full assistance with all activities of daily living. Example: A patient with end-stage cancer who is bedbound, requires help with all transfers, feeding, bathing, and toileting. **ECOG 5 (Dead):** This is included in the original scale but rarely documented clinically.
After assigning the ECOG score, document it clearly in the medical record: 'ECOG Performance Status: 1 (restricted in strenuous activity but fully ambulatory, capable of light work).' Update the ECOG score at every oncology visit, as functional status can change rapidly due to disease progression, treatment response, or intervening complications. Use the ECOG score to guide treatment decisions according to evidence-based guidelines: **ECOG 0–1:** Eligible for standard-dose chemotherapy, immunotherapy, targeted therapy, and most clinical trial enrollment. These patients have the best treatment tolerance and outcomes. Aggressive, curative-intent therapy is appropriate if clinically indicated. For example, a patient with newly diagnosed metastatic colorectal cancer and ECOG 1 is eligible for FOLFOX + bevacizumab or other combination regimens. **ECOG 2:** May receive chemotherapy, but dose reduction or less intensive regimens are often recommended to reduce toxicity risk. Many clinical trials exclude ECOG 2 patients. Careful risk-benefit assessment is needed—some patients tolerate treatment well, while others experience severe toxicity. For example, a patient with ECOG 2 and metastatic NSCLC might receive single-agent immunotherapy rather than platinum doublet chemotherapy. **ECOG 3–4:** Generally too debilitated for cytotoxic chemotherapy; best supportive care, palliative care, and symptom management are prioritized. Immunotherapy or targeted therapy may be considered in select cases if the functional decline is cancer-related and potentially reversible with treatment (e.g., EGFR-mutated NSCLC with large pleural effusion causing dyspnea—draining the effusion and starting osimertinib may improve ECOG status). However, most ECOG 3–4 patients have limited life expectancy (weeks to few months) and should receive hospice consultation. Incorporate ECOG status into prognostic discussions with patients and families. Poor ECOG status (3–4) is one of the strongest predictors of short survival across all cancer types, independent of disease burden. Use the score to frame goals-of-care conversations: 'Your current performance status is ECOG 3, which means your body is very weak from the cancer. Chemotherapy in this situation is more likely to cause harm than benefit. I recommend focusing on comfort and quality of life rather than intensive treatment.'
Medical oncologists and hematology-oncology fellows
Assess and document ECOG Performance Status at every clinic visit to determine chemotherapy eligibility and dose intensity. ECOG 0–1 patients can receive full-dose, standard-regimen chemotherapy with acceptable toxicity risk. ECOG 2 patients require individualized assessment—consider dose-reduced regimens, less toxic alternatives (single-agent vs combination), or treatment breaks to allow functional recovery. ECOG 3–4 patients are generally not candidates for cytotoxic chemotherapy due to high treatment-related mortality risk (30–50% in ECOG 4 patients receiving chemotherapy in some studies). Use ECOG status to frame shared decision-making: 'Your ECOG status is 1, which means you're a good candidate for combination chemotherapy with curative intent.' Conversely, 'Your ECOG status has declined to 3, which signals that chemotherapy is likely to cause more harm than benefit—let's discuss comfort-focused care.'
Clinical research coordinators and oncology trial investigators
ECOG Performance Status is a near-universal inclusion criterion for oncology clinical trials. Most phase II and III trials require ECOG 0–1 for enrollment, as these patients are most likely to tolerate investigational therapies and achieve protocol-defined endpoints. Some early-phase (phase I) trials or studies of less toxic therapies (immunotherapy, oral targeted agents) allow ECOG 2. Document ECOG score at screening, baseline, and every follow-up visit per protocol requirements. Be aware that ECOG scoring has inter-observer variability—standardize assessment within the research team by reviewing case examples and discussing borderline cases (e.g., is this patient ECOG 1 or 2?). When a patient's ECOG declines during trial participation, reassess protocol continuation—many trials mandate treatment discontinuation if ECOG worsens to ≥3 due to safety concerns.
Radiation oncologists and radiation oncology residents
Use ECOG Performance Status to predict radiation therapy tolerance and guide treatment intensity. ECOG 0–1 patients can undergo aggressive, curative-intent radiation (e.g., definitive chemoradiation for locally advanced NSCLC, head and neck cancer, or rectal cancer) with acceptable toxicity. ECOG 2 patients may require modified radiation regimens—shorter fractionation schedules (hypofractionation), omission of concurrent chemotherapy, or palliative-dose radiation rather than definitive-dose. ECOG 3–4 patients are often too frail for standard radiation courses; consider ultra-short palliative radiation (single 8 Gy fraction for bone metastases, 20 Gy/5 fractions for brain metastases) focused on symptom control. Document ECOG status in radiation planning notes and consult notes, as it impacts treatment intent (curative vs palliative), dose/fractionation, and expected outcomes.
Palliative care physicians and hospice nurses
ECOG Performance Status is one of the strongest predictors of survival and a key trigger for palliative care and hospice referrals. Patients with sustained ECOG 3–4 (especially if due to cancer rather than reversible causes like infection or fluid overload) have median survival measured in weeks to months and should receive early palliative care consultation. Use ECOG decline as an objective marker for goals-of-care discussions: a patient whose ECOG has worsened from 1 → 2 → 3 over 2–3 months despite treatment likely has progressive disease and should be offered hospice. Medicare hospice eligibility criteria for cancer patients include 'ECOG ≥3 or bedbound >50% of the day' as a clinical indicator of prognosis ≤6 months. Document ECOG trends over time ('ECOG 1 three months ago, now ECOG 3 despite chemotherapy—indicates disease progression and poor prognosis') to support hospice certification and communicate with primary oncologists about transitioning to comfort-focused care.
Oncology pharmacists and supportive care teams
Use ECOG Performance Status to guide supportive medication dosing and toxicity risk assessment. Patients with ECOG 3–4 have higher risk of chemotherapy-related toxicity and may require dose reductions, extended intervals between cycles, or prophylactic growth factor support (G-CSF) to prevent febrile neutropenia. ECOG status also informs antiemetic regimen selection: ECOG 0–1 patients can manage oral antiemetics at home, while ECOG 3 patients may need IV antiemetics due to poor oral intake. Additionally, ECOG decline prompts medication reconciliation—patients with ECOG 3–4 should discontinue medications that don't contribute to comfort (statins, vitamins, proton pump inhibitors for asymptomatic GERD) to reduce pill burden. Use ECOG status in medication therapy management discussions: 'Given your current ECOG 2 status and reduced activity level, I'm recommending prophylactic enoxaparin for VTE prevention during this chemotherapy cycle.'
Medical students, oncology fellows, and palliative care trainees
Teach ECOG Performance Status as a foundational skill in oncology and palliative care. Use standardized teaching cases to calibrate ECOG scoring: show videos or written vignettes of patients with ECOG 0–4 and have learners independently score, then discuss discrepancies to improve inter-rater reliability. Emphasize that ECOG is one of the most powerful prognostic indicators in oncology—across virtually all cancer types, ECOG 3–4 predicts median survival of weeks to months regardless of tumor biology. Teach learners to communicate ECOG-based prognosis sensitively: avoid saying 'You're too sick for chemotherapy' (sounds judgmental); instead say 'Your body's current strength level (ECOG 3) means chemotherapy is more likely to cause harm than benefit—I recommend focusing on comfort and quality time.' Use ECOG to teach shared decision-making: present treatment options tailored to ECOG status and elicit patient values ('Some patients with your ECOG status choose to try gentler chemotherapy, while others prioritize comfort—what matters most to you?').
The most clinically important distinction in ECOG scoring is between ECOG 0–1 (good performance status, eligible for standard treatment) and ECOG 2 (marginal performance status, treatment with caution). Most clinical trials require ECOG 0–1 for enrollment, and standard chemotherapy regimens are designed for this population. ECOG 2 represents a gray zone—some patients tolerate treatment well, while others experience severe toxicity and poor outcomes. When a patient is borderline between ECOG 1 and 2, consider the trajectory: Is this their baseline functional status, or have they recently declined? A patient who has been stable at ECOG 2 for months (due to chronic conditions or advanced age) may tolerate treatment better than a patient who declined from ECOG 0 to 2 over 2 weeks (likely progressive cancer or acute comorbidity). Use additional factors to guide decisions for ECOG 2 patients: age, comorbidities, lab abnormalities (cytopenias, organ dysfunction), social support, and patient preferences. When in doubt, start with dose-reduced or single-agent therapy and reassess tolerance.
ECOG Performance Status is a dynamic measure and should be documented at every oncology visit, not just at diagnosis. A patient can decline from ECOG 1 to 3 in 2–4 weeks due to disease progression, treatment complications (chemotherapy-induced anemia, infection, neuropathy), or intervening medical events (stroke, MI, deconditioning from hospitalization). Conversely, ECOG status can improve with effective treatment: a patient with ECOG 3 due to symptomatic brain metastases may improve to ECOG 1 after radiation. Track ECOG trends over time: stable or improving ECOG suggests treatment is working, while progressive ECOG decline despite therapy signals treatment failure and prompts reassessment of the care plan. Document ECOG at every visit in a standardized location in the medical record (e.g., vital signs section, oncology-specific template) to facilitate longitudinal tracking and quality metrics. Many EHRs have ECOG auto-calculation tools or smart phrases to streamline documentation.
The defining feature distinguishing ECOG 2 from ECOG 3 is the percentage of waking hours spent in bed or a chair. ECOG 2 patients are 'up and about >50% of waking hours but unable to work,' while ECOG 3 patients are 'confined to bed or chair >50% of waking hours with limited self-care.' To assess this accurately, ask the patient (or caregiver) directly: 'On a typical day, how many hours are you awake? Of those hours, how much time do you spend in bed or sitting in a chair versus up and moving around?' For example, a patient who is awake 14 hours/day and spends 10 hours in a recliner (>50%) is ECOG 3, even if they can walk to the bathroom and feed themselves. A patient who spends 4–5 hours napping but is otherwise up doing light activities is ECOG 2. This distinction is clinically important because ECOG 3 patients have much worse prognosis and treatment tolerance than ECOG 2, and many chemotherapy regimens are contraindicated at ECOG 3. Document clearly: 'Patient reports being awake ~12 hours daily, spends 8 hours sitting in recliner watching TV, remainder doing light activities. Estimated >50% time in bed/chair. ECOG 3.'
When a patient has poor ECOG status (3–4), systematically assess whether the functional decline is due to IRREVERSIBLE cancer progression or REVERSIBLE comorbidities. Reversible causes include: severe anemia (Hgb <7–8 g/dL, treatable with transfusion), symptomatic pleural/pericardial effusion (treatable with drainage), severe pain (treatable with opioid titration), delirium/encephalopathy (treatable infection, medication side effect), depression, severe deconditioning from prolonged hospitalization, electrolyte abnormalities (hypercalcemia, hyponatremia). A patient who is ECOG 4 due to anemia (Hgb 6 g/dL) may return to ECOG 1–2 after transfusion, restoring chemotherapy eligibility. In contrast, a patient who is ECOG 4 due to extensive leptomeningeal disease has irreversible decline and is not a candidate for aggressive treatment. Before concluding that a patient is 'too sick for chemotherapy,' address all reversible contributors to functional decline and reassess ECOG after optimization. Document: 'ECOG 3 on presentation, attributed to anemia (Hgb 7.2) and malignant pleural effusion. After transfusion (Hgb → 9.8) and thoracentesis (1.5L removed), patient improved to ECOG 1. Now eligible for chemotherapy.'
ECOG scoring has moderate inter-observer variability (kappa ~0.6–0.7), meaning different clinicians may assign different scores to the same patient. To improve consistency, use standardized descriptions and concrete examples when training staff and documenting scores. Instead of just writing 'ECOG 2,' document the specific functional limitations: 'ECOG 2: Patient is fully ambulatory, performs all self-care (bathing, dressing, eating) independently, but unable to work or do housework. Spends mornings doing light activities, naps 2–3 hours in afternoon. Out of bed ~60% of waking hours.' This provides context for future assessments and reduces ambiguity. Within oncology practices, calibrate ECOG scoring among providers by reviewing borderline cases in tumor board or quality meetings: 'This patient can shower and dress but needs a walker and spends most afternoons resting—is this ECOG 2 or 3?' Consensus-building improves reliability. Some institutions use structured ECOG assessment tools or patient-reported outcome surveys (e.g., asking patients to self-report activity level) to supplement clinician judgment.
ECOG Performance Status is one of the strongest prognostic indicators in oncology, independent of tumor stage, histology, and molecular features. Across all cancer types, patients with ECOG 3–4 have median survival measured in weeks to months, regardless of whether they have early-stage or metastatic disease. For example, a patient with stage I NSCLC but ECOG 4 (due to severe COPD or heart failure) has worse prognosis than a patient with stage IV NSCLC and ECOG 1. Multiple meta-analyses show that poor ECOG status is associated with shorter overall survival, higher treatment toxicity, and lower treatment response rates. Use ECOG status to contextualize prognosis in multidisciplinary discussions: 'This patient has resectable pancreatic cancer (stage IIA), but ECOG 3 due to malnutrition and deconditioning—even if we operate, perioperative mortality risk is very high. Should optimize performance status first.' ECOG is also incorporated into many cancer-specific prognostic models (e.g., International Prognostic Index for lymphoma, Memorial Sloan Kettering nomograms for various cancers) as a key variable.
Patients tend to overestimate their functional capacity due to optimism bias, cognitive impairment, or denial of illness. Studies show that patient-reported ECOG is often 1 point better than clinician-assessed ECOG (e.g., patient says ECOG 1, physician assesses ECOG 2). To improve accuracy, triangulate the ECOG score from three sources: (1) Direct observation during the clinic visit—is the patient ambulatory without assistance? Do they appear fatigued? (2) Patient self-report—'What activities can you do now vs before your diagnosis?' (3) Family/caregiver report—'How much time does your husband spend in bed or the recliner each day? Can he shower and dress himself?' Caregivers often provide more realistic assessments than patients. When there is discrepancy, favor the more objective assessment (observation + caregiver report) over patient self-report. Document: 'Patient reports doing 'pretty well' and rates himself as ECOG 1. However, wife reports he spends most of the day in a recliner, needs help with bathing, and hasn't left the house in 2 weeks. On exam, patient is cachectic, required wheelchair transport from parking lot. Assessed ECOG 3.'
A sustained decline in ECOG Performance Status often precedes radiographic evidence of disease progression by weeks to months. A patient whose ECOG declines from 1 → 2 → 3 over 6–8 weeks despite ongoing chemotherapy likely has progressive disease, even if imaging shows stable disease or only minimal growth. Functional decline (worsening fatigue, reduced activity tolerance, increasing bed time) reflects tumor burden, metabolic derangements, and cancer cachexia that may not yet be visible on CT scans. Use ECOG trends to guide treatment re-evaluation: 'Your imaging shows stable disease, but your performance status has worsened from ECOG 1 to 3 over the past two months, which suggests the cancer is progressing at a functional level even if scans don't show it yet. I recommend stopping current chemotherapy and considering a change in treatment strategy or transitioning to supportive care.' Conversely, improving or stable ECOG despite imaging progression (e.g., slow growth of asymptomatic lung nodules) may indicate indolent disease that doesn't require immediate intervention. Clinical status (ECOG) should outweigh radiographic findings in treatment decision-making.
Administering cytotoxic chemotherapy to patients with ECOG 3–4 carries extremely high risk of treatment-related mortality (TRM). Studies across multiple cancer types show that ECOG 3–4 patients receiving chemotherapy have 30–50% risk of death within 30 days of treatment, primarily from neutropenic sepsis, multi-organ failure, and inability to recover from chemotherapy-induced toxicity. The few ECOG 3–4 patients who survive chemotherapy often do not derive meaningful survival benefit compared to best supportive care. For this reason, most guidelines recommend AGAINST chemotherapy in ECOG 3–4 patients unless there is high likelihood of rapid response (e.g., chemosensitive lymphoma, germ cell tumor) or the poor ECOG is clearly cancer-related and reversible with treatment (e.g., rapidly accumulating malignant ascites causing respiratory compromise). In most cases, ECOG 3–4 patients should receive best supportive care, palliative care, and hospice consultation. When families request 'trying chemotherapy,' counsel them about the high risks: 'At ECOG 4, chemotherapy is more likely to shorten life than extend it. It may cause suffering without benefit. I strongly recommend focusing on comfort and quality time.' Document shared decision-making carefully if treatment is pursued despite ECOG 3–4.
Some institutions, clinical trials, and disease-specific guidelines use the Karnofsky Performance Status (KPS) scale (0–100% in 10-point increments) instead of ECOG. Knowing the conversions allows you to translate between scales: **ECOG 0 ≈ Karnofsky 90–100%** (normal activity, no complaints, no evidence of disease → able to carry on normal activity with minor symptoms). **ECOG 1 ≈ Karnofsky 70–80%** (normal activity with effort → able to care for self but unable to work). **ECOG 2 ≈ Karnofsky 50–60%** (unable to work, ambulatory and self-care → requires occasional assistance). **ECOG 3 ≈ Karnofsky 30–40%** (capable of limited self-care, >50% time in bed → severely disabled, hospitalization may be indicated). **ECOG 4 ≈ Karnofsky 10–20%** (completely disabled → very sick, hospitalization and active supportive care necessary). KPS offers finer gradations (10-point intervals provide more nuance), while ECOG is simpler and faster to assess. Most modern oncology trials use ECOG, but some neuro-oncology and palliative care literature uses KPS. Document both if needed: 'ECOG 2 (Karnofsky 60%): ambulatory, self-care intact, but unable to work or do housework.'
Your ECOG Performance Status score quantifies your overall functional capacity on a scale from 0 to 4. ECOG 0 means you are fully active and able to carry on all pre-disease activities without restriction. ECOG 1 indicates restriction in physically strenuous activity but the ability to carry out light work and ambulatory activities. ECOG 2 means you are ambulatory and capable of all self-care but unable to carry out any work activities, spending less than 50% of waking hours in bed. ECOG 3 indicates limited self-care ability and confinement to a bed or chair for more than 50% of waking hours. ECOG 4 means completely disabled, unable to carry on any self-care, and totally confined to bed or chair.
ECOG status is one of the most powerful prognostic indicators in oncology. Patients with ECOG 0–1 generally have better treatment responses, fewer complications, and longer survival across virtually all cancer types compared to those with ECOG 3–4.
Use the ECOG Performance Status at every oncology visit to assess and document the patient's functional capacity. It is a critical factor in determining eligibility for chemotherapy, immunotherapy, targeted therapy, and clinical trial enrollment. Most clinical trials require ECOG 0–1 for enrollment, and many standard chemotherapy regimens are not recommended for patients with ECOG 3–4 due to the high risk of treatment-related toxicity and poor expected benefit.
Beyond treatment decisions, ECOG status is essential for prognostic discussions, goals-of-care conversations, and palliative care referral timing. A sustained decline in ECOG status (e.g., from 1 to 3 over weeks) often signals disease progression or treatment failure and prompts reassessment of the treatment plan. It is also used by insurance payers and regulatory agencies as a criterion for treatment authorization.
The ECOG scale is inherently subjective and relies on the clinician's judgment of a patient's functional status, which can vary between observers. Studies have shown that physicians sometimes overestimate performance status compared to patient self-reports or objective measures. The scale has only 5 functional levels, providing limited granularity — a wide range of functional capacity can exist within a single ECOG category, particularly ECOG 2.
ECOG does not capture the cause of functional limitation. A patient may have poor performance status due to a treatable comorbidity (e.g., severe pain, depression, deconditioning from hospitalization) rather than irreversible cancer-related decline. Improving the underlying cause may restore functional status and treatment eligibility. The Karnofsky Performance Status (KPS) scale offers finer gradations (10-point increments from 0–100%) and may be more sensitive to changes, but ECOG remains the standard in most clinical trials and practice guidelines due to its simplicity.
For related assessments, see ASA Class, Clinical Frailty Scale and Katz ADL.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Classify preoperative physical status using the ASA I–VI system for anesthetic risk stratification. ASA III+ indicates significant systemic disease requiring special perioperative planning and precautions.
GeriatricsAssess frailty using the Rockwood Clinical Frailty Scale (CFS 1–9): Very Fit to Terminally Ill. Used for ICU triage, surgical risk stratification, and goals-of-care discussions in elderly patients.
GeriatricsAssess independence in six basic activities of daily living using the Katz Index. Scores range from 0 (dependent) to 6 (fully independent). Pair with [Morse Fall Scale](/tools/morse-fall-scale) for fall risk and [Timed Up and Go](/tools/get-up-and-go) for mobility.